



August 16, 2017

Fosun Pharma Selects Medidata's Unified Platform for Clinical Development in China

Leading Chinese Healthcare Group Adopts Medidata's Cloud Technology to Bring Operational Efficiencies to its R&D Programs

NEW YORK & SHANGHAI--(BUSINESS WIRE)-- [Medidata](#) (NASDAQ: MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, today announced an enterprise agreement with leading Chinese healthcare group, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s subsidiary Shanghai Fosun Pharmaceutical Development Co., Ltd.(Fosun Pharma). Fosun Pharma has adopted the [Medidata Clinical Cloud](#)® platform to improve data management capabilities and bring operational efficiencies to its clinical studies in China.

Fosun Pharma is implementing Medidata Rave®, a unified EDC and CDMS solution for capturing, managing and reporting patient data, across its generics development pipeline, accelerating treatments in such therapeutic areas as cardiovascular, oncology, anti-infection and central nervous system (CNS). The leading Chinese clinical R&D company is also leveraging Rave Study Design and Build Essentials (SDBE) training. Taught on [RaveX](#)—the latest version of Rave—SDBE will equip Fosun Pharma's study teams with the fundamentals required to develop and update electronic Case Report Forms (eCRFs), ultimately optimizing study implementation and ensuring trial timelines are met.

"We are proud to be Fosun Pharma's cloud-based, clinical technology platform of choice and a key addition to its roster of partners," said Edwin Ng, Medidata's vice president of field operations, APeJ (Asia Pacific except Japan). "We look forward to powering Fosun Pharma's clinical studies with Medidata's flexible, cutting-edge technology as they strive to become a first-class enterprise in the global healthcare market and a key player in the bioequivalence space."

About Medidata

[Medidata](#) is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20170816006052/en/): <http://www.businesswire.com/news/home/20170816006052/en/>

Medidata

Investor:

Anthony D'Amico, +1 732-767-4331

adamico@mdsol.com

or

Media:

Medidata Solutions

Erik Snider, +1 646-362-2997

esnider@mdsol.com

Source: Medidata

News Provided by Acquire Media